UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of ~~February~~May, 2026

Commission File Number 001-40772

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

94 Shlomo Shmelzer Road Petah Tikva 4970602, Israel

Petah Tikva 4970602, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form

~~Form~~ 20-F ☒ ~~Form~~ Form 40-F ☐

EXPLANATORY NOTE

On ~~February~~May 1114, 2026, Cellebrite DI Ltd. (the “Registrant” or “Cellebrite”) issued a press release titled “Cellebrite Announces ~~Record Fourth~~First-Quarter ~~and~~2026 ~~Full-Year 2025~~ Results.” A copy of this press release is furnished as Exhibit 99.1 herewith.

The GAAP financial statements tables contained in the press release attached to this report on Form 6-K are incorporated by reference into the Registrant’s registration statements on Form S-8 (File Nos. 333-260878, 333-278130 and 333-~~278130~~293973) filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2021, ~~and~~ March 21, 2024 and March 3, 2026, respectively, and Form F-3 (File No. 333-259826) filed with the SEC on September 13, 2022.

EXHIBIT INDEX

Exhibit		Description
99.1		Press release titled “Cellebrite Announces ~~Record Fourth~~First-Quarter ~~and~~2026 ~~Full-Year 2025~~ Results” (furnished herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellebrite DI Ltd.
Date: February 11, 2026	By:	/s/ David Barter
Date: May 14, 2026	By:	/s/ David Barter
		David Barter
		Chief Financial Officer

Filing Compare · Cellebrite DI Ltd.